Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA
Authors:
- Marina DanilenkoMDMarina Danilenko
- Sharanya NathSharanya Nath
- Jack BainesJBJack Baines
- Freya GordonFGFreya Gordon
- Swathi MeruguSMSwathi Merugu
- Lisa M. AllinsonLALisa M. Allinson
- Aaron PottsAPAaron Potts
- Bethany CollinsBCBethany Collins
- Angharad GoodmanAGAngharad Goodman
- Samuel E. KidmanSKSamuel E. Kidman
- Ciaron McAnultyCMCiaron McAnulty
- David JamiesonDJDavid Jamieson
Open Access
- 27 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9466
Abstract
Neuroblastoma (NB) is an aggressive childhood cancer requiring intensive multimodal therapies in high-risk (HRNB) patients. Currently, invasive surgical biopsies are required to classify NB risk group and assign treatment based on the tumour genetic profile. Circulating tumour DNA (ctDNA) obtained from blood samples can be used to identify tumour biomarkers. Here we applied targeted next-generation sequencing (tNGS) using a panel of 42 genes to analyse 32 NB ctDNA samples for the presence of single-nucleotide variants and copy number changes from 28 patients in all NB risk groups. In two additional ctDNA samples, droplet digital PCR was used to detect hotspot ALK variants. Pathogenic mutations with a variant allele frequency (VAF) > 1% were identified in 13/32 (41%) ctDNA samples. ALK and PTPN11 were the most frequent, each being detected in 4/32 (13%) samples, together with oncogene amplifications. Targeted NGS of ctDNA detected actionable variants, including those absent in the diagnostic primary tumour due to spatial and temporal heterogeneity. Our findings confirm the usefulness of ctDNA in detecting genetic abnormalities in NB.Keywords
Funding Information
- Cancer Research UK (C8594/A23804)
- Cancer Research UK (CRCPSC-Dec21\100002)
- Sir Bobby Robson Foundation, Little Princess Trust (CCLGA 2016 08)
- Children’s Cancer North, a CR UK Centre (CTRQQR-2021\100003)
- Action Medical Research/Great Ormond Street Hospital Charity (GN2390)
- Horizon Europe-Mission Cancer THRIVE (101136622)
This publication has 41 references indexed in Scilit:
- Loss of ALK hotspot mutations in relapsed neuroblastomaGenes, Chromosomes and Cancer, 2022
- Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patientsGenes, Chromosomes and Cancer, 2019
- Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnosticsVirchows Archiv, 2019
- Neuroblastoma: clinical and biological approach to risk stratification and treatmentCell and tissue research, 2018
- REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense VariantsThe American Journal of Human Genetics, 2016
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in NeuroblastomaCancer Cell, 2014
- Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2Current Protocols in Human Genetics, 2013
- Methods for isolation of cell-free plasma DNA strongly affect DNA yieldClinica Chimica Acta, 2011
- Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumorsCancer Genetics and Cytogenetics, 2008
- A case of Noonan's syndrome with possible associated neuroblastomaPediatric Radiology, 2000